Hologic, Inc. (HOLX) Financials

NASDAQ:HOLX

Market Cap

17.64B

Total Revenue

Gross Profit

Operating Income

1.23B

Net Income

982.70M

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
revenue	2,530,700,000	2,705,000,000	2,832,700,000	3,058,800,000	3,217,900,000	3,367,300,000	3,776,400,000	5,632,300,000	4,862,800,000	--
costOfRevenue	1,285,200,000	1,272,300,000	1,269,400,000	1,437,800,000	1,521,200,000	2,059,200,000	1,548,900,000	1,836,500,000	1,865,400,000	--
grossProfit	1,245,500,000	1,432,700,000	1,563,300,000	1,621,000,000	1,696,700,000	1,308,100,000	2,227,500,000	3,795,800,000	2,997,400,000	--
researchAndDevelopmentExpenses	203,200,000	214,900,000	232,100,000	232,800,000	218,700,000	232,200,000	222,500,000	276,300,000	283,400,000	--
sellingAndMarketingExpenses	331,700,000	363,000,000	415,100,000	498,600,000	544,600,000	564,900,000	484,600,000	561,200,000	630,300,000	--
generalAndAdministrativeExpenses	259,800,000	261,000,000	267,300,000	343,300,000	366,100,000	332,300,000	356,000,000	433,200,000	407,700,000	--
sellingGeneralAndAdministrativeExpenses	591,500,000	624,000,000	682,400,000	841,900,000	910,700,000	897,200,000	840,600,000	994,400,000	1,038,000,000	--
operatingExpenses	908,500,000	949,100,000	1,004,200,000	1,137,200,000	1,188,700,000	1,181,400,000	1,102,800,000	1,312,900,000	1,366,600,000	1,227,200,000
operatingIncome	279,700,000	455,100,000	548,600,000	1,370,200,000	-237,900,000	134,400,000	1,105,000,000	2,480,300,000	1,640,200,000	1,227,200,000
totalOtherIncomeExpensesNet	-68,300,000	-102,200,000	10,800,000	896,100,000	-784,200,000	-229,700,000	-103,100,000	-119,200,000	-52,000,000	--
ebitda	447,200,000	965,300,000	1,051,800,000	949,700,000	1,002,200,000	597,500,000	1,514,100,000	2,885,800,000	2,104,700,000	1,227,200,000
depreciationAndAmortization	113,800,000	491,400,000	465,400,000	449,200,000	480,300,000	463,100,000	409,100,000	405,500,000	464,500,000	--
interestIncome	1,300,000	1,300,000	700,000	3,800,000	6,300,000	4,600,000	4,300,000	1,400,000	12,900,000	--
interestExpense	220,600,000	205,500,000	155,300,000	153,200,000	148,700,000	140,800,000	116,500,000	93,600,000	95,100,000	102,200,000
incomeBeforeTax	48,100,000	177,200,000	415,300,000	1,230,500,000	-418,600,000	-95,300,000	1,001,900,000	2,361,100,000	1,588,200,000	1,227,200,000
incomeTaxExpense	30,800,000	45,600,000	84,500,000	475,000,000	-307,300,000	-55,100,000	-108,600,000	491,400,000	286,200,000	244,500,000
netIncome	17,300,000	131,600,000	330,800,000	755,500,000	-111,300,000	-40,200,000	1,115,200,000	1,871,500,000	1,302,000,000	982,700,000
eps	0.06	0.47	1.18	2.7	-0.4	-0.15	4.24	7.28	5.18	--
epsdiluted	0.06	0.45	1.16	2.64	-0.4	-0.15	4.21	7.21	5.13	--
weightedAverageShsOut	275,499,000	280,566,000	280,213,000	279,811,000	275,105,000	269,413,000	262,727,000	257,046,000	251,527,000	--
weightedAverageShsOutDil	278,360,000	289,537,000	286,156,000	285,653,000	275,105,000	269,413,000	264,613,000	259,706,000	253,845,000	--
costAndExpenses	2,193,700,000	2,221,400,000	2,273,600,000	2,575,000,000	2,709,900,000	3,240,600,000	2,651,700,000	3,149,400,000	3,232,000,000	1,227,200,000
otherExpenses	-3,600,000	-11,000,000	26,600,000	12,900,000	7,600,000	52,000,000	39,700,000	42,200,000	45,200,000	1,227,200,000

Key Facts

Industry

Medical Instruments & Supplies

Sector

Healthcare

Headquarters

Marlborough, MA, US

Website

hologic.com

CEO

Mr. Stephen P. MacMillan

Employees

6944

About the Company

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.